-

Octave Bioscience to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a leading precision care company that is delivering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that its management team will be attending the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY.

About Octave Bioscience, Inc.

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes. For more information, visit www.octavebio.com.

Contacts

Caroline Corner
ICR Healthcare
caroline.corner@icrhealthcare.com

Industry:

Octave Bioscience, Inc.

Release Versions
English

Contacts

Caroline Corner
ICR Healthcare
caroline.corner@icrhealthcare.com

More News From Octave Bioscience, Inc.

Octave® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, is pleased to announce that as part of its long-term succession plan, entrepreneur and Octave founder, William Hagstrom, will transition into the role of Chairman of the Board. Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immedi...

Octave® Bioscience, Inc. Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate Multi-Analyte Protein Biomarker Test for Parkinson’s Disease Assessments

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis and other neurodegenerative diseases, today announced that it has been awarded a $10M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used for discovery, development, and validation of a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic, helping t...

Octave® Bioscience, Inc. Presents Data Highlighting Application and Impact of its Precision Care Solution at MSMilan2023

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc. announced new data shared in nine poster presentations at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting....
Back to Newsroom